(Q37505185)

English

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements

scientific article published on 12 January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements (English)

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

1 reference

ChEBI release 2020-05-28

pharmacogenomics

1 reference

based on heuristic

inferred from title

papillary thyroid cancer

1 reference

based on heuristic

inferred from title

1

object named as

D Neil Hayes

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

object named as

Karen E Weck

15

0 references

Monika K Krzyzanowska

object named as

Monika K Krzyzanowska

4

0 references

17

object named as

Ezra E W Cohen

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

author name string

Amy S Lucas

2

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Tawee Tanvetyanon

3

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Christine H Chung

5

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Barbara A Murphy

6

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Jill Gilbert

7

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Ranee Mehra

8

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Dominic T Moore

9

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Arif Sheikh

10

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Janelle Hoskins

11

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Michele C Hayward

12

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Ni Zhao

13

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Wendi O'Connor

14

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Roger B Cohen

16

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

language of work or name

0 references

publication date

12 January 2012

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

18

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

7

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

2056-2065

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

23 August 2017

Molecular diagnostics and predictors in thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

23 August 2017

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

23 August 2017

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

23 August 2017

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

23 August 2017

Motesanib diphosphate in progressive differentiated thyroid cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

23 August 2017

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

23 August 2017

Phase II trial of sorafenib in advanced thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

23 August 2017

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

23 August 2017

BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

23 August 2017

Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

23 August 2017

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

23 August 2017

Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

23 August 2017

Mutations of the BRAF gene in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

23 August 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

23 August 2017

Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

14 September 2017

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

14 September 2017

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

14 September 2017

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

14 September 2017

Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

26 June 2018

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

26 June 2018

RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

2 September 2018

Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

2 September 2018

A phase II study of gefitinib in patients with advanced thyroid cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

2 September 2018

The prevalence and prognostic value of BRAF mutation in thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

2 September 2018

Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

2 September 2018

Pyrosequencing of clinically relevant polymorphisms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

2 September 2018

BRAF mutations in papillary carcinomas of the thyroid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

2 September 2018

High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

2 September 2018

Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

2 September 2018

The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5157199

3 December 2018

Distant Metastases in Differentiated Thyroid Carcinoma: A Multivariate Analysis of Prognostic Variables*

1 reference

https://pubmed.ncbi.nlm.nih.gov/22241789

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC

1 reference

https://pubmed.ncbi.nlm.nih.gov/22241789

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thyroid carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22241789

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane

1 reference

https://pubmed.ncbi.nlm.nih.gov/22241789

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management guidelines for patients with thyroid nodules and differentiated thyroid cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22241789

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution

1 reference

https://pubmed.ncbi.nlm.nih.gov/22241789

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BRAF Mutation in Papillary Thyroid Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22241789

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22241789

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake

1 reference

https://pubmed.ncbi.nlm.nih.gov/22241789

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-11-0563

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

release_lx6ajhbggrdgtdudaubptfgnme

1 reference

https://api.fatcat.wiki/v0/release/lx6ajhbggrdgtdudaubptfgnme

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37505185&oldid=1843766790"